Anne Schumacher, Event Manager, Pharma- High Growth Markets at UBM , in an email interview with AD Pradeep Kumar talks about the novel features of CPhI China 2014, Chinese pharma market, Indo-China pharma trade prospects and also gives an overview of the last year's event.
Schumacher is responsible for managing and developing CPhI and P-MEC China, CPhI and P-MEC India and also CPhI Istanbul.
Kindly provide the details on the novel features of CPhI China 2014?
CPhI China will host the 5th annual CPhI “China and World” CEO Summit, a further networking event with substantial support from a vibrant speaker team of government officials, regulatory agencies and leading pharmaceutical companies. Titled “The Strategies and Actions of China’s Pharmaceutical Industry in the New 3.0 Times”, the conference is one of the show’s main attractions and has been designed to educate the industry and provide vital information to those looking to break into China’s attractive pharmaceutical market. It is certainly not to be missed if you are planning your next business move within the region.
Furthermore, our zonal layout enhances our customer experience and eases navigation. All co-located events are in designated zones, and this year we are pleased to announce the launch of a finished dosages area- reflecting the growing demand and diversification of dosage forms (e.g. tablets, capsules and transdermal patches).
What is the expected domestic as well as international participation for this year's event?
Overall, 30,000 visitors are expected to attend CPhI China over the course of its three show days. The event will provide opportunities to meet with industry professionals and aid business development in one of pharma’s largest markets.
CPhI China is attracting more and more visitors each year. They include specialists from general management, marketing & sales, purchasing, production, quality control, engineering and R&D. There will also be more than 2,500 exhibitors, both domestic and international, showcasing their offerings.
What is the expected Indian participation in particular?
We have seen some of India’s largest and most innovative companies (39 in total) taking up space at the event, with prominent industry businesses including Alchem International Ltd, Global Vision, Supriya Lifescience Ltd, Granules India Ltd and Hetero Drugs Ltd.
What are your expectations on Indo -China pharma trade ?
Whilst traditionally direct rivals in the global pharma market, what we are now seeing is increasing acts of mutualism between these two countries and this will lead to a greater trade. We are already seeing this in place with the India-China pharmaceutical memorandum, signed last year in order to expand trade and facilitate market access for each. The memorandum will help increase access in both directions – currently access to India is seen as easier for Chinese companies than vice versa, with clearance taking around a year as opposed to 3-5 years.
Could you kindly give an overview of pharma industry in China
The Chinese pharmaceutical market is the third largest in the world and current trends suggest the market will enjoy a period of prosperity and growth, with predictions that pharma sales value will soon overtake that of Japan. It has been forecast that the market will grow by 17.7 per cent annually to 2017. It’s an exciting market to be part of in terms of domestic production alone. An ageing population brings increased demand for healthcare and life sciences, whilst the global need for affordable APIs means the importance of China within the pharmaceutical field has never been greater. Events such as CPhI China therefore provide the ideal platform to build a bridge between domestic and international buyers and suppliers to address these industry needs.
What are your comments on the current status of the API market of China?
The Chinese pharmaceutical ingredients market is undergoing a great deal of change and akin to some of the broader changes taking place within the Indian market with both seeing huge levels of growth and development. Last year alone China’s API industry revenue was RMB 382 billion. As mentioned previously, there is now an increased global need for affordable APIs and China is currently the go-to destination with by far the largest share.
What was the outcome of CPhI China 2013 ?
Attendance rates far exceeded expectation and CPhI and P-MEC China, alongside co-located events BioPh, ICSE, InnoPack and LabWorld, hosted a record breaking more than 2,400 companies both local and international and attracted more than 30,000 visitors from 133 countries throughout the world.
On-site at CPhI China 2013, the “China and World” Medical Forum proved highly insightful and valuable for attendees. Having received substantial support from a vibrant speaker team of government and leading pharmaceutical companies, the forum showcased hot topic seminars and conferences. These covered the latest policies and regulations within the pharmaceutical industry and the practical applications of new technology. Furthermore, the Buyer Sourcing Event, with more than 60 buyers, 280 sessions and over 90 per cent successful match rate, has provided a catalyst for increased business connections in the region.
This result shows that CPhI China is now at the centre of pharmaceutical business connections within the region.